drugset

drugset / Trial / NCT01895946

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

NCT01895946 ↗

Phase 1 Completed 33 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

Timeline

Start: 2013-12
Primary completion: 2015-02
Completion: 2015-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capivasertib	Small molecule	—	Oral

Indications